Monoclonal antibodies bind to their target molecule via two identical and highly specific binding regions, located on the tips of both arms of the antibody. In bispecific antibodies, the two binding regions are not identical, and each region is directed against a different molecule or different site (epitope) on the same molecule. By binding two different molecules instead of one, bispecific antibodies can bind even more specifically to a certain target cell, or can connect a target cell with a white blood cell that will kill the target cell.
Genmab has developed its own proprietary platform for bispecific antibody generation, DuoBody technology. The DuoBody platform is an innovative platform for the discovery and development of bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease. Bispecific antibodies bind to two different epitopes either on the same, or on different targets (also known as dual-targeting) which may improve the antibodies’ specificity and efficacy in inactivating the disease target cells. DuoBody molecules are unique in combining the benefits of bispecificity with the strengths of conventional antibodies, which allows DuoBody molecules to be administered and dosed as other antibody therapeutics. Genmab's DuoBody platform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at standard bench as well as commercial manufacturing scale.
To read more about the DuoBody platform, visit DuoBody.com. To read a white paper on the DuoBody technology published in PNAS, click here.
Back to top